Cell-based high-content approach for SARS-CoV-2 neutralization identifies unique monoclonal antibodies and PI3K pathway inhibitors.
Carly R. Cabel, Briana A. Guzman, Elaheh Alizadeh, Shuaizhi Li, Cameron Holberg, Chonlarat Wichaidit, Darren A. Cusanovich, Andrew L. Paek, Gregory R. J. Thatcher, Koenraad Van Doorslaer, Rachel S. Nargi, Rachel E. Sutton, Naveenchandra Suryadevara, James E. Crowe, Robert H. Carnahan, , Curtis A. Thorne
This study uses high-throughput screens in human cells with authentic SARS-CoV-2 virus to identify neutralizing monoclonal antibodies and kinase inhibitors with minimal host toxicity.
Frontiers in Cell and Developmental Biology · May 22, 2025Peer-reviewedPharmacology & Toxicology